H6D.STU Haleon PLC
- Market cap
- EUR 38.9B
- P/E
- 18.1x
- P/B
- 1.97x
- ROE
- 10.1%
- Dividend yield
- 1.36%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is H6D.STU undervalued?
Graham numberH6D.STU trades 25.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Haleon PLC fundamental analysis
No fundamental analysis for Haleon PLC yet.
Haleon PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Haleon PLC
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, an…
Full company profileHaleon PLC financial statements
Haleon PLC annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 9.89B | 9.55B | 10.9B | 11.3B | 11.2B | 11.0B |
| Gross Profit | - | 5.91B | 5.95B | 6.58B | 6.75B | 6.82B | 7.08B |
| Operating Income | - | 1.60B | 1.64B | 1.83B | 2.00B | 2.21B | 2.41B |
| EBITDA | - | - | - | 2.18B | 2.35B | 2.63B | 2.86B |
| Net Income | - | 1.15B | 1.39B | 1.06B | 1.05B | 1.44B | 1.67B |
| EPS | - | 0.12 | 0.15 | 0.11 | 0.11 | 0.16 | 0.19 |
| Balance Sheet | |||||||
| Total Assets | - | 34.1B | 34.5B | 34.8B | 34.1B | 34.3B | 32.6B |
| Total Liabilities | - | 7.91B | 7.97B | 18.4B | 17.3B | 18.1B | 16.1B |
| Shareholders' Equity | - | 26.1B | 26.4B | 16.3B | 16.6B | 16.2B | 16.4B |
| Cash & Short-term Investments | - | 334M | 347M | 606M | 994M | 2.20B | 1.26B |
| Cash Flow | |||||||
| Operating Cash Flow | 786M | 1.41B | 1.36B | 2.06B | 2.10B | 2.30B | 2.63B |
| Capital Expenditure | 190M | 222M | 298M | 328M | 336M | 318M | 413M |
| Free Cash Flow | - | 1.09B | 1.06B | 1.74B | 1.76B | 1.98B | 2.22B |
| Ratios | |||||||
| ROE | - | 4.4% | 5.3% | 6.5% | 6.3% | 8.9% | 10.1% |
| ROA | - | 3.4% | 4.0% | 3.0% | 3.1% | 4.2% | 5.1% |
| Net Profit Margin | - | 11.6% | 14.6% | 9.8% | 9.3% | 12.8% | 15.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Haleon PLC dividends
- Dividend yield
- 1.36%
- Forward dividend
- -
- Payout ratio
- 36.7%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | GBP 612M | 0.07 | 36.7% |
| 2024 | GBP 570M | 0.06 | 39.5% |
| 2023 | GBP 388M | 0.04 | 37.0% |
| 2022 | GBP 2.68B | 0.29 | 253.0% |
| 2021 | GBP 1.15B | 0.12 | 82.6% |
| 2020 | EUR 2.37B | 0.26 | 207.1% |
| 2019 | EUR 1.15B | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Haleon PLC
- Insiders 6.40%
- Institutions 0.02%
- Public & others 93.58%
- Shares outstanding 4.62B
- Free float 2.54B
Haleon PLC company profile
- Company name
- Haleon PLC
- Ticker
- H6D.STU
- Exchange
- Stuttgart Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 22,800
- Fiscal year end
- December
- Address
- Building 5, Weybridge, United Kingdom, KT13 0NY
- Phone
- 44 1932 822000
- Website
- haleon.com
About Haleon PLC
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Haleon PLC management
10- Mr. Brian McNamaraCEO & Exec. Director · born 1967
- Mr. Tobias HestlerCFO & Exec. Director · born 1972
- Ms. Amy LanducciHead of Digital and Technology
- Mr. Bjarne Philip TellmannGen. Counsel · born 1967
- Ms. Tamara RogersChief Marketing Officer · born 1969
- Ms. Mairead NayagerChief HR Officer · born 1975
- Mr. Bart DerdeHead of Quality and Supply Chain · born 1969
- Mr. Filippo LanziHead of EMEA & LatAm
- Ms. Teri LyngHead of Transformation & Sustainability · born 1962
- Ms. Jooyong LeeHead of Strategy and Office of the CEO · born 1977